At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
00460 SIHUAN PHARM
Closed 11-19 16:08:17
0.690
+0.000
0.00%
High0.700Low0.680Vol6.30M
Open0.690D1 Closing0.690Amplitude2.90%
Mkt Cap6.43BTradable Cap6.43BTotal Shares9.32B
T/O4.36MT/O Rate0.07%Tradable Shares9.32B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Private companies are Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) biggest owners and were hit after market cap dropped HK$559m
Simply Wall St.  ·  11-16
Private companies are Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) biggest owners and were hit after market cap dropped HK$559m
BRIEF-Sihuan Pharma Announces Proposed Spin-Off Of Xuanzhu Biopharm
reuters  ·  11-13
BRIEF-Sihuan Pharma Announces Proposed Spin-Off Of Xuanzhu Biopharm
Sihuan Pharma - Proposed Spin-off of Xuanzhu Biopharm and Listing on Main Board of Stock Exchange
THOMSON REUTERS  ·  11-12
Sihuan Pharma - Proposed Spin-off of Xuanzhu Biopharm and Listing on Main Board of Stock Exchange
Sihuan Pharma - Unit to Further Acquire 3.6177% Stake in Xuanzhu Biopharmaceutical for RMB308 Mln
THOMSON REUTERS  ·  11-12
Sihuan Pharma - Unit to Further Acquire 3.6177% Stake in Xuanzhu Biopharmaceutical for RMB308 Mln
Sihuan Pharmaceutical to Conduct Up to HK$500 Million Share Buyback: Shares Jump 29%
MT Newswires Live  ·  10-07
Sihuan Pharmaceutical to Conduct Up to HK$500 Million Share Buyback: Shares Jump 29%
BUZZ-HK-listed Sihuan Pharma gains over 40% on share buyback plan
Reuters  ·  10-07
BUZZ-HK-listed Sihuan Pharma gains over 40% on share buyback plan
Sihuan Pharma Says to Conduct on-Market Share Repurchase of up to HK$500 Mln, Including HK$5.4 Mln Repurchased in H1
THOMSON REUTERS  ·  10-06
Sihuan Pharma Says to Conduct on-Market Share Repurchase of up to HK$500 Mln, Including HK$5.4 Mln Repurchased in H1
BRIEF-Sihuan Pharma Says To Conduct On-Market Share Repurchase Of Up To HK$500 Mln
Reuters  ·  10-06
BRIEF-Sihuan Pharma Says To Conduct On-Market Share Repurchase Of Up To HK$500 Mln
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Simply Wall St.  ·  09-30
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sihuan Pharmaceutical Holdings Group H1 Gross Margin 64.1%
THOMSON REUTERS  ·  09-23
Sihuan Pharmaceutical Holdings Group H1 Gross Margin 64.1%
Sihuan Pharmaceutical Unit's Obesity Drug Gets Investigational New Drug Nod from NMPA
MT Newswires Live  ·  08-30
Sihuan Pharmaceutical Unit's Obesity Drug Gets Investigational New Drug Nod from NMPA
Sihuan Pharma - Semaglutide Injection Developed by Huisheng Biopharmaceutical for Weight Loss Indication Obtained Ind Approval From Nmpa
THOMSON REUTERS  ·  08-30
Sihuan Pharma - Semaglutide Injection Developed by Huisheng Biopharmaceutical for Weight Loss Indication Obtained Ind Approval From Nmpa
Sihuan Pharmaceutical's Unit's Diabetes Drug Gets NMPA's Nod
MT Newswires Live  ·  08-14
Sihuan Pharmaceutical's Unit's Diabetes Drug Gets NMPA's Nod
Sihuan Pharmaceutical's Unit's Diabetes Drug Gets NMPA's Nod
MT Newswires Live  ·  08-14
Sihuan Pharmaceutical's Unit's Diabetes Drug Gets NMPA's Nod
BRIEF-Sihuan Pharma Says Insulin Degludec Injection Huiyouda's Drug Registration Approved By NMPA
Reuters  ·  08-14
BRIEF-Sihuan Pharma Says Insulin Degludec Injection Huiyouda's Drug Registration Approved By NMPA
Sihuan Pharma - Insulin Degludec Injection Huiyouda Developed by Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa
THOMSON REUTERS  ·  08-14
Sihuan Pharma - Insulin Degludec Injection Huiyouda Developed by Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa
Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China
MT Newswires Live  ·  08-06
Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China
Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China
MT Newswires Live  ·  08-06
Sihuan Pharmaceutical Obtains Exclusive Distribution Rights for Cellontech Korea's CartiZol in China
Sihuan Pharmaceutical Unit Gets China Nod to Register Type II Diabetes Drug; Shares Jump 8%
MT Newswires Live  ·  08-06
Sihuan Pharmaceutical Unit Gets China Nod to Register Type II Diabetes Drug; Shares Jump 8%
Sihuan Pharmaceutical Unit Gets China Nod to Register Type II Diabetes Drug; Shares Jump 8%
MT Newswires Live  ·  08-06
Sihuan Pharmaceutical Unit Gets China Nod to Register Type II Diabetes Drug; Shares Jump 8%

Introduction

Company Name.
SIHUAN PHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sihuan Pharmaceutical Holding Group Ltd. is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.
Issue price:
--